Accelerating Drug Development through Early-Stage Assessments
Early-stage developability assessments, focusing on both therapeutic efficacy and manufacturability, play a vital role in identifying viable drug candidates and eliminating less promising ones. Moreover, by employing a quality-by-design (QbD) framework, pharmaceutical companies can develop efficient manufacturing processes and flexible formulations adaptable to evolving requirements.
In our latest article, explore:
- The benefits of early developability assessments for identifying promising candidates
- How quality-by-design principles significantly enhance long-term efficiency
- Why designing advanceable formulations with an eye toward bioavailability, scalability, stability, manufacturability, and compliance accelerates timelines and enhance cost-effectiveness in drug development
Read Full Article